Cite
How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
MLA
Ferrero, Dario, et al. “How Many Patients Can Proceed from Chronic Myeloid Leukaemia Diagnosis to Deep Molecular Response and Long-Lasting Imatinib Discontinuation? A Real Life Experience.” British Journal of Haematology, vol. 176, no. 4, Feb. 2017, pp. 669–71. EBSCOhost, https://doi.org/10.1111/bjh.13983.
APA
Ferrero, D., Cerrano, M., Crisà, E., Aguzzi, C., Giai, V., & Boccadoro, M. (2017). How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience. British Journal of Haematology, 176(4), 669–671. https://doi.org/10.1111/bjh.13983
Chicago
Ferrero, Dario, Marco Cerrano, Elena Crisà, Chiara Aguzzi, Valentina Giai, and Mario Boccadoro. 2017. “How Many Patients Can Proceed from Chronic Myeloid Leukaemia Diagnosis to Deep Molecular Response and Long-Lasting Imatinib Discontinuation? A Real Life Experience.” British Journal of Haematology 176 (4): 669–71. doi:10.1111/bjh.13983.